Reaction: Filgotinib to 1 product
- Reaction
- Reaction type
- hydrolysis
- Direction
- Major circulating metabolite?
- Yes
- Spontaneous?
- No
- Activity
- active
- References
- Namour F, Diderichsen PM, Cox E, Vayssiere B, Van der Aa A, Tasset C, Van't Klooster G: Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection. Clin Pharmacokinet. 2015 Aug;54(8):859-74. doi: 10.1007/s40262-015-0240-z. [Article]
- Namour F: Author's Reply to Srinivas: "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection". Clin Pharmacokinet. 2015 Dec;54(12):1297-8. doi: 10.1007/s40262-015-0336-5. [Article]
- Namour F, Fagard L, Van der Aa A, Harrison P, Xin Y, Tasset C: Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor. Br J Clin Pharmacol. 2018 Dec;84(12):2779-2789. doi: 10.1111/bcp.13726. Epub 2018 Oct 4. [Article]
- Comments
- Not Available
- Enzymes
Enzyme Km Vmax Role Cocaine esterase Not Available Not Available confirmed Liver carboxylesterase 1 Not Available Not Available confirmed